about
High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.Apelin promotes lymphangiogenesis and lymph node metastasis.Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patientsErythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsKi67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis InhibitorsCirculating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesotheliomaTrabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.Mechanism of tumour vascularization in experimental lung metastases.Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.The evidence for and against different modes of tumour cell extravasation in the lung: diapedesis, capillary destruction, necroptosis, and endothelialization.BARD1 serum autoantibodies for the detection of lung cancer.Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma.Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer.Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.Cell migration or cytokinesis and proliferation?--revisiting the "go or grow" hypothesis in cancer cells in vitro.Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.Afatinib restrains K-RAS–driven lung tumorigenesis
P50
Q27853357-AD83AE11-9EBC-4286-9E6A-D594E9366798Q34100995-3B044D15-B976-4B58-A4FA-771D6A10C519Q34373472-C2085336-7354-4B04-B2C4-006DC920EE5BQ35025478-D4A9AF01-27DE-4368-8D4C-C6608E1AB9C5Q35039240-888470D2-5C2D-4B05-B9DC-25D6BB32A4A7Q35043887-0F36D2B9-8DE7-4B36-A814-A7372ADA7161Q35678741-697F3169-D30D-40AC-9490-4E7DBD31197FQ36081391-FA9A2357-1C1A-4D28-A726-801C5B82CAC4Q36237312-F1F79DA6-22C4-45C5-A957-072362EBCC48Q37594406-219ACE3C-9123-4461-9ECD-A92B0C787992Q38752503-E798B85B-0D52-4646-B116-083B28D96CA8Q38870822-DBA78D98-5718-419D-92D4-4FB216AC298AQ38947459-B57A8EF4-1A12-43A5-9E2B-6F10BA47FF95Q38959812-442C4188-21AA-4BF1-B4AF-21CC7D72B465Q39062503-CE8B320F-739A-4A30-8CDE-CAD637EC3EC5Q41281453-C9523AC4-5B5F-4F5F-B6A4-6C439AFE2E3DQ41460456-B62587E2-BFE9-48EB-A006-6D476AA93C8AQ47133994-6EE64929-A1E6-4A8A-90FC-F36461739889Q47743683-6718014C-310B-4DA5-86D3-6337EE7D4538Q51509080-78838683-552A-4406-9922-A6114A6B3936Q53055406-EC8D1441-01D7-46EA-AC2C-5E913EC85BF3Q53093213-F103186D-D041-43E1-93B1-9C6F23FC129CQ54171446-1426E0DB-95FF-48A4-979D-84A3A41D9379Q61714947-8B616B6F-A56F-400A-8FB6-42E6892AFA10
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-6567-3965
@en
name
Viktoria Laszlo
@ast
Viktoria Laszlo
@en
Viktoria Laszlo
@es
Viktoria Laszlo
@nl
type
label
Viktoria Laszlo
@ast
Viktoria Laszlo
@en
Viktoria Laszlo
@es
Viktoria Laszlo
@nl
prefLabel
Viktoria Laszlo
@ast
Viktoria Laszlo
@en
Viktoria Laszlo
@es
Viktoria Laszlo
@nl
P106
P31
P496
0000-0002-6567-3965